- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00296179
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
July 25, 2008 updated by: Sanofi
Comparison of Zolpidem Tartrate Extended-Release vs. Placebo in Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder(MDD) or Untreated MDD Relapse, When Used Concomitantly With Escitalopram
To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.
Study Overview
Study Type
Interventional
Enrollment
372
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
MAJOR INCLUSION CRITERIA:
- Must experience sleep disturbances at least 3 nights/week, based on historical data
- Must meet the diagnostic requirements for Major Depressive Disorder
- Must have QIDS-SR16 score between 6 and 15
- Must be either newly diagnosed or show symptoms of relapse/recurrence of depression while not on medication
- Age 21-64, inclusive
- Women must use a medically acceptable form of contraception (steroidal contraceptive, double-barrier, or intra-uterine device) during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization.
- Subject must be stabilized on all ongoing long-term medication therapy for at least 28 days prior to screening visit.
MAJOR EXCLUSION CRITERIA:
- Severity of depressive episode had been rated as "severe" or "severe with psychotic features."
- History of a suicide attempt or suicidal ideation.
- History of mania, manic episode or bipolar disease.
- Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.
- Use of prescription and non-prescription sedative drugs given for the purpose of sleep induction or to relieve jet lag
- Any abnormal pre-study laboratory values that require clinical intervention
- Prior failure to respond to escitalopram therapy for depression
- Current depressive episode requiring inpatient hospitalization.
- Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous 28 days.
- History of drug addiction, alcoholism, or drug abuse.
- A positive urine drug screen for medication that would interfere with the assessment of the study medication.
- Known allergy to zolpidem, escitalopram or any of their excipients
- History of sleep apnea
- History of myasthenia gravis
- The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.
- Pregnant or breastfeeding
- Subject is participating in another clinical trial, or has completed another clinical trial within 28 days prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Efficacy: Patient-reported TST
|
Secondary Outcome Measures
Outcome Measure |
---|
Difference in relapse rates in patients receiving placebo and patients receiving zolpidem MR during 4 month follow-up period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
June 1, 2007
Study Completion
December 7, 2022
Study Registration Dates
First Submitted
February 23, 2006
First Submitted That Met QC Criteria
February 23, 2006
First Posted (Estimate)
February 24, 2006
Study Record Updates
Last Update Posted (Estimate)
July 28, 2008
Last Update Submitted That Met QC Criteria
July 25, 2008
Last Verified
July 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- GABA Agents
- Sleep Aids, Pharmaceutical
- GABA-A Receptor Agonists
- GABA Agonists
- Zolpidem
Other Study ID Numbers
- PM_L_0166
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on zolpidem tartrate
-
Mutual Pharmaceutical Company, Inc.CompletedHealthy | Therapeutic Equivalency
-
Transcept PharmaceuticalsCompleted
-
Mutual Pharmaceutical Company, Inc.Completed
-
University of PennsylvaniaNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedInsomnia | Insomnia ChronicUnited States
-
Eisai Inc.CompletedInsomniaUnited States, Spain, United Kingdom, Italy, Germany, France, Canada
-
Xijing HospitalGuangzhou University of Chinese Medicine; University of Melbourne; Tianjin UniversityCompletedDisorder of ConsciousnessChina
-
Eisai Inc.Purdue Pharma LPCompleted
-
SanofiCompletedInsomniaUnited States
-
Johns Hopkins UniversityCompleted
-
University of Southern CaliforniaRecruitingPain, Postoperative | Spine Fusion | Lumbar Spine Degeneration | Lumbar Spine SpondylosisUnited States